Alliancebernstein L.P. Lowers Holdings in Quanterix Co. (NASDAQ:QTRX)

Alliancebernstein L.P. reduced its stake in shares of Quanterix Co. (NASDAQ:QTRX) by 25.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,439,805 shares of the company’s stock after selling 825,798 shares during the quarter. Alliancebernstein L.P. owned 6.33% of Quanterix worth $25,935,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of QTRX. Vanguard Group Inc. grew its stake in shares of Quanterix by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 2,217,225 shares of the company’s stock worth $23,569,000 after purchasing an additional 19,386 shares during the period. William Blair Investment Management LLC purchased a new stake in Quanterix during the fourth quarter worth $11,290,000. Easterly Investment Partners LLC grew its position in Quanterix by 9.0% during the fourth quarter. Easterly Investment Partners LLC now owns 954,995 shares of the company’s stock valued at $10,152,000 after buying an additional 78,862 shares during the period. Geode Capital Management LLC increased its holdings in Quanterix by 2.2% in the third quarter. Geode Capital Management LLC now owns 858,667 shares of the company’s stock valued at $11,131,000 after buying an additional 18,231 shares in the last quarter. Finally, State Street Corp raised its position in shares of Quanterix by 2.2% in the third quarter. State Street Corp now owns 836,443 shares of the company’s stock worth $10,840,000 after acquiring an additional 18,050 shares during the period. 86.48% of the stock is owned by institutional investors and hedge funds.

Quanterix Stock Down 4.3 %

Shares of NASDAQ QTRX opened at $5.94 on Monday. The firm has a market cap of $230.33 million, a price-to-earnings ratio of -5.60 and a beta of 1.35. The company’s 50-day simple moving average is $7.66 and its 200-day simple moving average is $10.40. Quanterix Co. has a 52-week low of $5.62 and a 52-week high of $21.89.

Quanterix (NASDAQ:QTRX) last posted its quarterly earnings data on Monday, March 17th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.03). Quanterix had a negative return on equity of 11.74% and a negative net margin of 30.12%. The firm had revenue of $35.16 million during the quarter, compared to analyst estimates of $34.93 million. Equities research analysts anticipate that Quanterix Co. will post -0.98 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on QTRX. Canaccord Genuity Group dropped their target price on Quanterix from $20.00 to $15.00 and set a “buy” rating on the stock in a research report on Tuesday, March 18th. Scotiabank reissued an “outperform” rating on shares of Quanterix in a report on Tuesday, March 25th.

Quanterix Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.